Netherlands· NL-8d14acfe8272

Mitoxantron Accord 2 mg/ml, concentraat voor oplossing voor infusie

A mitoxantrone product containing mitoxantrondihydrochloride, registered in Netherlands by Accord Healthcare B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC L01DB07

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about mitoxantrondihydrochlorideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Mitoxantrone is registered in 14 of 19 countries.

Countries holding a registration under ATC L01DB07 (mitoxantrone), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
7 of them publish a price we can compare per daily dose

Search mitoxantrone products by name

Mitoxantrone · ATC L01DB07

14 / 19 countries

Belgiumprice
Canada
Denmark
Finlandprice
Franceprice
Germany
Japan
Netherlands
Norwayprice
Polandprice
Spainprice
Sweden
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: MITOXANTRONDIHYDROCHLORIDE
Manufacturer: Accord Healthcare B.V.
Country: Netherlands (NL)
ATC code: L01DB07
ATC class: Mitoxantrone
Defined daily dose: 10 mg, P
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
26663

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

405 interactions on record for mitoxantrone.

Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check mitoxantrone against other medicines How interaction checks work

Mitoxantrone · interactions on record

405 records

31 severe
199 moderate
15 minor
160 info

Most severe, free to view

DolasetronA04AA04severe
CladribineL01BB04severe
Talimogene laherparepvecL01XL02severe
Talimogen laherparepvecL01XX51severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Mitoxantrone in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mitoxantrone products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

Austria · Ebexantron
Belgium · Mitoxantrone Sandoz
Bulgaria · Митоксантрон Ебеве
Germany · Mitoxantron Hexal, Novantron
Denmark · Mitoxantron "ebewe"
Estonia · Onkotrone
Spain · Mitoxantrona Accord, Novantrone
Finland · Mitoxantron Ebewe
France · Mitoxantrone Accord
United Kingdom (Northern Ireland) · Mitoxantrone Accord Healthcare, Onkotrone Injection
Greece · Mitoxan
Hungary · Onkotrone
Italy · Onkotrone
Lithuania · Onkotrone
Luxembourg · Mitoxantrone Sandoz
Latvia · Onkotrone
Malta · Onkotrone
Norway · Mitoxantron Ebewe
Poland · Mitoxantron Sandoz
Portugal · Mitoxantrona Pharmis, Mitoxantrone Baxter
Romania · Onkotrone
Sweden · Mitoxantron Ebewe
Slovenia · Onkotrone
Slovakia · Onkotrone

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/2c4642a5-e825-4dd3-95a8-c9d2496d0c05
GET /v1/drugs/2c4642a5-e825-4dd3-95a8-c9d2496d0c05?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h26663_smpc.pdf",
  "strength": null,
  "atc_label": "Mitoxantrone",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg26663",
  "excipients": [
    "AZIJNZUUR (E 260), GECONCENTREERD",
    "NATRIUMACETAAT 0-WATER (E 262)",
    "NATRIUMCHLORIDE",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "MITOXANTRONDIHYDROCHLORIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h26663.pdf",
  "authorised_at": "2003/07/03",
  "procedure_number": "NL/H/0412/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "26663",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about mitoxantrone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console